Skip to main content

Advertisement

SpringerLink
Log in

Choosing a Regimen for Prophylaxis of Graft-versus-Host Disease

  • Disease Management
  • Published:
BioDrugs Aims and scope Submit manuscript

Summary

Graft-versus-host disease (GVHD), both acute and chronic, continues to be a major problem after allogeneic haemopoietic stem cell transplantation. Combinations of pharmacological agents, such as methotrexate and cyclosporin, are most effective in patients transplanted from human leucocyte antigen (HLA)-identical related donors, but less so in patients transplanted from HLA-nonidentical or unrelated (‘alternative’) donors. Additional agents such as tacrolimus and rapamycin are currently being tested. The approach to T cell depletion still requires further definition, especially in regard to the prevention of leukaemic relapse. The addback of donor cells with some delay post-transplant may offer an intriguing alternative to intensified conditioning regimens for the prevention of leukaemic recurrence without necessarily increasing the risk of GVHD. All patients transplanted should be entered into well-designed studies in order to accrue data and advance our knowledge at the fastest rate possible.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Billingham RE. The biology of graft-versus-host reactions. In: The Harvey Lectures. New York: Academic Press, 1966: 21–78

    Google Scholar 

  2. Anderson KC, Weinstein HJ. Transfusion-associated graft-versus-host disease. N Engl J Med 1990; 323: 315–21

    Article  PubMed  CAS  Google Scholar 

  3. Juji T, Takahashi K, Shibata Y, et al. Post-transfusion graft-versus-host disease in immunocompetent patients after cardiac surgery in Japan. N Engl J Med 1989; 321: 56

    PubMed  CAS  Google Scholar 

  4. Hess AD, Fischer AC. Immune mechanisms in cyclosporine-induced syngeneic graft-versus-host disease. Transplantation 1989; 48: 895–900

    Article  PubMed  CAS  Google Scholar 

  5. Mitsuyasu RT, Champlin RE, Gale RP, et al. Treatment of donor bone marrow with monoclonal anti-T-cell antibody and complement for the prevention of graft-versus-host disease. Ann Intern Med 1986; 105: 20–6

    PubMed  CAS  Google Scholar 

  6. Truitt RL, LeFever AV, Shih CCY, et al. Graft-versus-leukemia effect. In: Burakoff SJ, Deeg HJ, Ferrara J, et al. editors. Graft-versus-host disease: immunology, pathophysiology, and treatment. New York: Marcel Dekker, 1990: 177–204

    Google Scholar 

  7. Kernan NA. Graft failure following transplantation of T-cell-depleted marrow. In: Burakoff SJ, Deeg HJ, Ferrara J, et al., editors. Graft-versus-host disease: immunology, pathophysiology and treatment. New York: Marcel Dekker, 1990: 557–68

    Google Scholar 

  8. Sullivan KM, Storb R, Buckner CD, et al. Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms. N Engl J Med 1989; 320: 828–34

    Article  PubMed  CAS  Google Scholar 

  9. Jones RJ, Vogelsang GB, Hess AD, et al. Induction of graft-versus-host disease after autologous bone marrow transplantation. Lancet 1990; I: 754–7

    Google Scholar 

  10. Ferrara JLM, Deeg HJ. Graft-versus-host disease. N Engl J Med 1991; 324: 667–74

    Article  PubMed  CAS  Google Scholar 

  11. Antin JH, Ferrara JLM. Cytokine dysregulation and acute graft-versus-host disease. Blood 1992; 80: 2964–8

    PubMed  CAS  Google Scholar 

  12. Cocks BG, Chang CC, Carballido JM, et al. A novel receptor involved in T-cell activation. Nature 1995; 376: 260–3

    Article  PubMed  CAS  Google Scholar 

  13. Wyss-Coray T, Mauri-Hellweg D, Baumann K, et al. The B7 adhesion molecule is expressed on activated human T cells: functional involvement in T-T cell interactions. Eur J Immunol 1993; 23(9): 2175–80

    Article  PubMed  CAS  Google Scholar 

  14. Linsley PS, Greene JL, Tan P, et al. Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes. J Exp Med 1992; 176: 1595–604

    Article  PubMed  CAS  Google Scholar 

  15. Linsley PS, Wallace PM, Johnson J, et al. Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule. Science 1992; 257: 792–5

    Article  PubMed  CAS  Google Scholar 

  16. Deeg HJ, Cottier-Fox M. Clinical spectrum and pathophysiology of acute graft-versus-host disease. In: Burakoff SJ, Deeg HJ, Ferrara J, et al., editors. Graft-versus-host disease: immunology, pathophysiology, and treatment. New York: Marcel Dekker, 1990: 311–35

    Google Scholar 

  17. Deeg HJ. Graft-versus-host disease: host and donor views. Semin Hematol 1993; 30: 110–8

    PubMed  CAS  Google Scholar 

  18. Ringdén O, Deeg HJ. Clinical spectrum of graft-versus-host disease. In: Ferrara JLM, Deeg HJ, Burakoff S, editors. Graft-versus-host disease. 2nd ed. New York: Marcel Dekker, 1997: 525–59

    Google Scholar 

  19. Sullivan KM, Deeg HJ, Sanders J, et al. Hyperacute GVHD in patients not given immunosuppression after allogeneic marrow transplantation. Blood 1986; 67: 1172–5

    PubMed  CAS  Google Scholar 

  20. Deeg HJ, Huss R. Acute graft-versus-host disease. In: Atkinson K, editor. Clinical bone marrow transplant: a reference textbook. Cambridge: Cambridge University Press, 1994: 297–311

    Google Scholar 

  21. Ringden O. Viral infections and graft-versus-host disease. In: Burakoff SJ, Deeg HJ, Ferrara J, et al., editors. Graft-versus-host disease: immunology, pathophysiology, and treatment. New York: Marcel Dekker, 1990: 467–86

    Google Scholar 

  22. Rappeport JM. Syngeneic and autologous graft-versus-host disease: immunology, pathology and treatment. In: Burakoff SJ, Deeg HJ, Ferrara J, et al., editors. Graft-versus-host disease. New York: Marcel Dekker, 1990: 455–66

    Google Scholar 

  23. Martin PJ, Hansen JA, Buckner CD, et al. Effects of in vitro depletion of T cells in HLA-identical allogeneic marrow grafts. Blood 1985; 66: 664–72

    PubMed  CAS  Google Scholar 

  24. Cobbold S, Martin G, Waldmann H. Monoclonal antibodies for the prevention of graft-versus-host disease and marrow graft rejection. Transplantation 1986; 42: 239–47

    Article  PubMed  CAS  Google Scholar 

  25. Martin PJ, Hansen JA, Torok-Storb B, et al. Graft failure in patients receiving T cell-depleted HLA-identical allogeneic marrow transplants. Bone Marrow Transplant 1988; 3: 445–56

    PubMed  CAS  Google Scholar 

  26. Hale G, Cobbold S, Waldmann H. T cell depletion with Campath-1 in allogeneic bone marrow transplantation. Transplantation 1988; 45: 753–9

    Article  PubMed  CAS  Google Scholar 

  27. Slavin S, Waldmann H, Or R, et al. Prevention of graft-versus-host disease in allogeneic bone marrow transplantation for leukemia by T cell depletion in vitro prior to transplantation. Transplant Proc 1985; 17: 465–7

    Google Scholar 

  28. Vallera DA, Blazar BR. T cell depletion for graft-versus-host-disease prophylaxis. Transplantation 1989; 47: 751–60

    Article  PubMed  CAS  Google Scholar 

  29. Wagner JE, Donnenberg AD, Noga SJ, et al. Lymphocyte depletion of donor bone marrow by counterflow centrifugal elutriation: results of a phase I clinical trial. Blood 1988; 72: 1168

    PubMed  CAS  Google Scholar 

  30. Marmont AM, Horowitz MM, Gale RP, et al. T-cell depletion of HLA-identical transplants in leukemia. Blood 1991; 78: 2120–30

    PubMed  CAS  Google Scholar 

  31. Nimer SD, Giorgi J, Gajewski JL, et al. Selective depletion of CD8+ cells for prevention of graft-versus-host disease after bone marrow transplantation. Transplantation 1994; 57: 82–7

    Article  PubMed  CAS  Google Scholar 

  32. Maraninchi D, Mawas C, Guyotat D, et al. Selective depletion of marrow-T cytotoxic lymphocytes (CD8) in the prevention of graft-versus-host disease after allogeneic bone marrow transplantation. Transpl Int 1988; 1: 91–4

    PubMed  CAS  Google Scholar 

  33. Roy DC, Tantravahi R, Murray C, et al. Natural history of mixed chimerism after bone marrow transplantation with CD6-depleted allogeneic marrow: a stable equilibrium. Blood 1990; 75: 296–304

    PubMed  CAS  Google Scholar 

  34. Martin PJ. Donor CD8 cells prevent allogeneic marrow graft rejection in mice: potential implications for marrow transplantation in humans. J Exp Med 1993; 178: 703–12

    Article  PubMed  CAS  Google Scholar 

  35. Storb R, Epstein RB, Graham TC, et al. Methotrexate regimens for control of graft-versus-host disease in dogs with allogeneic marrow grafts. Transplantation 1970; 9: 240–6

    Article  PubMed  CAS  Google Scholar 

  36. Santos GW, Tutschka PJ, Brookmeyer R, et al. Cyclosporine plus methylprednisolone versus cyclophosphamide plus methylprednisolone as prophylaxis for graft-versus-host disease: a randomized double-blind study in patients undergoing allogeneic marrow transplantation. Clin Transplant 1987; 1: 21–8

    Google Scholar 

  37. Powles RL, Clink HM, Spence D, et al. Cyclosporin A to prevent graft-versus-host disease in man after allogeneic bone marrow transplantation. Lancet 1980; I: 327–9

    Article  Google Scholar 

  38. Storb R, Deeg HJ, Fisher LD, et al. Cyclosporine v methotrexate for graft-v-host disease prevention in patients given marrow grafts for leukemia: long-term follow-up of three controlled trials. Blood 1988; 71: 293–8

    PubMed  CAS  Google Scholar 

  39. Deeg HJ, Storb R, Weiden PL, et al. Cyclosporin A and methotrexate in canine marrow transplantation: engraftment, graft-versus-host disease, and induction of tolerance. Transplantation 1982; 34: 30–5

    Article  PubMed  CAS  Google Scholar 

  40. Deeg HJ, Storb R, Appelbaum FR, et al. Combined immunosuppression with cyclosporine and methotrexate in dogs given bone marrow grafts from DLA-haploidentical littermates. Transplantation 1984; 37: 62–5

    Article  PubMed  CAS  Google Scholar 

  41. Storb R, Deeg HJ, Whitehead J, et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft-versus-host disease after marrow transplantation for leukemia. N Engl J Med 1986; 314: 729–35

    Article  PubMed  CAS  Google Scholar 

  42. Forman SJ, Blume KG, Krance RA, et al. A prospective randomized study of acute graft-versus-host disease in 107 patients with leukemia: methotrexate/prednisone vs. cyclosporine A/prednisone. Transplant Proc 1987; 19: 2605–7

    PubMed  CAS  Google Scholar 

  43. Storb R, Pepe M, Anasetti C, et al. What role for prednisone in prevention of acute graft-versus-host disease in patients undergoing marrow transplants? Blood 1990; 76: 1037–45

    PubMed  CAS  Google Scholar 

  44. Chao NJ, Schmidt GM, Niland JC, et al. Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease. N Engl J Med 1993; 329: 1225–30

    Article  PubMed  CAS  Google Scholar 

  45. Fay JW, Nash RA, Winegard J, et al. FK506-based immunosuppression for prevention of graft-versus-host disease (GVHD) after unrelated marrow donor (UMD) transplantation [abstract]. Transplant Proc 1995; 27: 1374

    PubMed  CAS  Google Scholar 

  46. Nash RA, Etzioni R, Storb R, et al. Tacrolimus (FK506) alone or in combination with methotrexate or methylprednisolone for the prevention of acute graft-versus-host disease after marrow transplantation from HLA-matched siblings: a single-center study. Blood 1995; 85: 3746–53

    PubMed  CAS  Google Scholar 

  47. Blazar BR, Taylor PA, Snover DC, et al. Murine recipients of fully mismatched donor marrow are protected from lethal graft-versus-host disease by the in vivo administration of rapamycin but develop an autoimmune-like syndrome. J Immunol 1993; 151(10): 5726–41

    PubMed  CAS  Google Scholar 

  48. Yu C, Storb R, Deeg HJ, et al. Synergism between mycophenolate mofetil and cyclosporine in preventing graft-versus-host disease in lethally irradiated dogs given DLA-nonidentical unrelated marrow grafts [abstract]. Blood 1995; A577

    Google Scholar 

  49. Deeg HJ. Prophylaxis and treatment of acute graft-versus-host disease: current state, implications of new immunopharmacologic compounds and future strategies to prevent and treat acute GVHD in high-risk patients. Bone Marrow Transplant 1994; 14: S56–60

    PubMed  Google Scholar 

  50. Jones JM, Wilson R, Bealmear PM. Mortality and gross pathology of secondary disease in germfree mouse radiation chimeras. Radiat Res 1971; 45(3): 577–88

    Article  PubMed  CAS  Google Scholar 

  51. Storb R, Prentice RL, Buckner CD, et al. Graft-versus-host disease and survival in patients with aplastic anemia treated by marrow grafts from HLA-identical siblings: beneficial effect of a protective environment. N Engl J Med 1983; 308: 302–7

    Article  PubMed  CAS  Google Scholar 

  52. Vossen JM, Heidt PJ, van den Berg H, et al. Prevention of infection and graft-versus-host disease by suppression of intestinal microflora in children treated with allogeneic bone marrow transplantation. Eur J Clin Microbiol Infect Dis 1990; 9: 14–23

    Article  PubMed  CAS  Google Scholar 

  53. Passweg JR, Rowlings PA, Klein JP, et al. Influence of isolation on outcome of bone marrow transplantation [abstract]. American Society of Hematology 37th Annual Meeting: 1995 Dec 1-5, A459

  54. Wagner J, Lebkowski J, Fahey S, et al. Isolation and enrichment of primitive CD34+/HLA-DR-human hematopoietic stem cells by counterflow elutriation followed by a soybean agglutinin depletion and CD34+ positive selection [abstract]. Bone Marrow Transplant 1992; 216: D211

    Google Scholar 

  55. Kolb HJ, Mittermüller J, Clemm C, et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990; 76: 2462–5

    PubMed  CAS  Google Scholar 

  56. Slavin S, Naparstek E, Nagler A, et al. Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes. Exp Hematol 1995; 23(14): 1553–62

    PubMed  CAS  Google Scholar 

Download references

Acknowledgements

Supported in part by PHS grants CA09515, CA18029, CAI8221 and HL36444 from the National Institutes of Health, DHHS, Bethesda, MD, USA. JWL is also supported by a grant from Catholic University Medical College, Seoul, South Korea.

Author information

Authors and Affiliations

  1. Transplantation Biology Program, Fred Hutchinson Cancer Research Center, and the University of Washington, Department of Medicine, 1124 Columbia Street, M318, Seattle, Washington, 98104-2092, USA

    Jong Wook Lee &  H. Joachim Deeg

Authors
  1. Jong Wook Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. Joachim Deeg
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lee, J.W., Deeg, H.J. Choosing a Regimen for Prophylaxis of Graft-versus-Host Disease. BioDrugs 7, 15–22 (1997). https://doi.org/10.2165/00063030-199707010-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00063030-199707010-00003

Keywords

Search

Navigation